A novel strategy for tumour therapy combining cell apoptosis and active immunity induced by caspy2, a zebrafish caspase

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2271-2281

  Liu, Lei ^a   Deng, Hongxin ^a   Wang, Yongsheng ^a   Chen, Ping ^a   Yang, Yang ^a   Yang, Hanshuo ^a   Chen, Xiancheng ^a   Chen, Lijuan ^a   Zhu, Wen ^a   Liang, Shufang ^a   Yang, Jinliang ^a   Qian, Zhiyong ^a   Li, Jiong ^a   Wen, Yanjun ^a   Kan, Bin ^a   Mao, Yongqiu ^a   Zhao, Xia ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cationic liposome; Dual effect; Immune response; Plasmid DNA

Indexed keywords

CASPASE; CASPY PROTEIN, ZEBRAFISH; PRIMER DNA; ZEBRAFISH PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; MOUSE; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; ZEBRA FISH;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CASPASES; DNA PRIMERS; MICE; ZEBRAFISH; ZEBRAFISH PROTEINS;

DANIO RERIO; EUKARYOTA; MAMMALIA; MUS;

EID: 72949124652     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00693.x     Document Type: Article

References (41)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972 26 : 239 257.
2. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000 407 : 784 788.
3. Bhutia S, Maiti TK. Targeting tumors with peptides from natural sources. Trends Biotechnol. 2008 26 : 210 217.
4. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 2008 9 : 1002 1011.
5. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005 5 : 231 237.
6. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 267 : 1456 1462.
7. Bellamy CO, Malcomson RD, Harrison DJ, et al. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol. 1995 6 : 3 16.
8. Lauber K, Blumenthal SG, Waibel M, et al. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell. 2004 14 : 277 287.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998 392 : 245 252.
10. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998 392 : 86 9.
11. Bellone M, Iezzi G, Rovere P, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol. 1997 159 : 5391 5399.
12. Leitner WW, Restifo NP. DNA vaccines and apoptosis: to kill or not to kill J Clin Invest. 2003 112 : 22 4.
13. Zitvogel L, Casares N, Péquignot MO, et al. The immune response against dying tumor cells. Adv Immunol. 2004 84 : 131 179.
14. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005 202 : 1691 1701.
15. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003 170 : 4905 4913.
16. Sasaki S, Amara RR, Oran AE, et al. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol. 2001 19 : 543 547.
17. Hoffmann TK, Meidenbauer N, Dworacki G, et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000 60 : 3542 3549.
18. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998 281 : 1312 1316.
19. Masumoto J, Zhou W, Chen FF, et al. Caspy, a zebrafish caspase, activated by ASC oligomerization is required for pharyngeal arch development. J Biol Chem. 2003 278 : 4268 4276.
20. Matzinger P. The danger model: a renewed sense of self. Science. 2002 296 : 301 305.
21. Ding HF, Fisher DE. Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med. 2002 34 : 451 469.
22. Michaeli D. Vaccines and monoclonal antibodies. Semin Oncol. 2005 32 : 82 6.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 65 : 55 63.
24. Wei YQ, Zhao X, Kariya Y, et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res. 1996 56 : 1104 1110.
25. Mashino K, Sadanaga N, Tanaka F, et al. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol Cancer Ther. 2002 1 : 785 794.
26. Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004 199 : 437 448.
27. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006 12 : 693 698.
28. + cytotoxic T cells. Leukemia. 2001 15 : 1619 1626.
29. Barczyk K, Kreuter M, Pryjma J, et al. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer. 2005 116 : 167 173.
30. Renz A, Berdel WE, Kreuter M, et al. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood. 2001 98 : 1542 1548.
31. Miller JF, Morahan G, Allison J. Extrathimic acquisition of tolerance by T lymphocytes. Cold Spring Harb Symp Quant Bio. 1989 2 : 807 813.
32. Chattergoon MA, Kim JJ, Yang JS, et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol. 2000 18 : 974 979.
33. Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA. 1993 90 : 4645 4649.
34. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998 188 : 1359 1368.
35. + T cell help. J Exp Med. 1997 186 : 65 70.
36. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol. 2000 165 : 4246 4253.
37. + T cells engaging class II molecules in cholesterol-rich domains. J Immunol. 2002 168 : 1172 1180.
38. + T cell responses in antitumor immunity. Curr Opin Immunol. 1998 10 : 588 594.
39. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998 187 : 693 702.
40. + T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol. 2006 176 : 1447 1455.
41. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997 18 : 263 266.